1-20 of 21
Lauren C. Pinter-Brown
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors

Tatyana Feldman, Enrica Marchi, Stephen D. Smith, Adam J. Olszewski, Auris O Huen, Zachary D. Epstein-Peterson, Don A. Stevens, Alexander N. Starodub, Eric J. Feldman, Cristina P Rodriguez, John C. Reneau, Jonathan E. Brammer, Ahmad H. Mattour, Lauren C. Pinter-Brown, Rachelle Perea, Patrick Henrick, Joyoti Dey, Alyssa Fasciano, Rahul Karnik, Sagar Agarwal, Ashwin Gollerkeri, Jared Gollob, Aditi Shastri, Stefan K. Barta
Journal: Blood
Blood (2024) 144 (Supplement 1): 4433.
https://doi.org/10.1182/blood-2024-210301
Published: 2024
Journal Articles

Glofitamab in Combination with Rituximab Plus Ifosfamide, Carboplatin, and Etoposide Shows Favorable Efficacy and Manageable Safety in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Eligible for Stem Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: Results from a Phase Ib Study

Catherine S. Diefenbach, Paolo F. Caimi, Nakhle S Saba, Fernando Vargas Madueno, Mehdi Hamadani, Luis E. Fayad, Peter A. Riedell, Andrew Gillis-Smith, Stephen Simko, Victor Orellana-Noia, Maria Filippou-Frye, Amy V. Kapp, James Relf, Linda Lundberg, Lauren C. Pinter-Brown
Journal: Blood
Blood (2024) 144 (Supplement 1): 987.
https://doi.org/10.1182/blood-2024-198452
Published: 2024
Journal Articles

Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule

Christiane Querfeld, Julia J Scarisbrick, Oleg Akilov, Payal Arora, Yi Liu, Martine Bagot, Raul Cordoba, Richard Cowan, Alejandro Martín García-Sancho, Larisa J Geskin, Auris O Huen, Jatin Jadwani, Steven Morris, Pablo L Ortiz-Romero, Akshaya Patel, Lauren C. Pinter-Brown, Ramon M Pujol, Pietro Quaglino, Nakhle S Saba, Ragini Vuppugalla, Henry Zhao, Youn H. Kim
Journal: Blood
Blood (2024) 144 (Supplement 1): 3056.
https://doi.org/10.1182/blood-2024-200596
Published: 2024
Journal Articles

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial

Neha Mehta-Shah, Pier Luigi Zinzani, Eric D. Jacobsen, Jasmine Zain, Monica Mead, Carla Casulo, Giuseppe Gritti, Lauren C. Pinter-Brown, Koji Izutsu, Ohad S Bentur, David Sidransky, Jonathan E. Brammer, Barbara Pro, Christopher P. Fox, Steven Horwitz
Journal: Blood
Blood (2024) 144 (Supplement 1): 3061.
https://doi.org/10.1182/blood-2024-203577
Published: 2024
Journal Articles

A Phase 1 Study of Adding Pitavastatin to Venetoclax-Based Therapy in AML and CLL/SLL

Elizabeth A. Brem, Susan M. O'Brien, Pamela S. Becker, Deepa Jeyakumar, Lauren C. Pinter-Brown, Christina Kirk, Thomas Taylor, Blake Johnson, Stephanie Osorio, Roberta Buono, David A Fruman
Journal: Blood
Blood (2023) 142 (Supplement 1): 5940.
https://doi.org/10.1182/blood-2023-188086
Published: 2023
Journal Articles

Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Aditi Shastri, Eric J Feldman, Alexander N Starodub, Tatyana Feldman, Cristina P Rodriguez, Zachary D. Epstein-Peterson, Don A. Stevens, Adam J Olszewski, Auris O Huen, Pierluigi Porcu, John C Reneau, Stefan K. Barta, Enrica Marchi, Ahmad H Mattour, Lauren C. Pinter-Brown, Rachelle Perea, Sean Donohue, Joyoti Dey, Sagar Agarwal, Rahul Karnik, Ashwin Gollerkeri, Jared Gollob, Stephen D Smith
Journal: Blood
Blood (2023) 142 (Supplement 1): 3081.
https://doi.org/10.1182/blood-2023-181130
Published: 2023
Journal Articles

Baseline Immunoglobulin G and Immune Function in Lymphoma: A Retrospective Analysis

Christopher Grant, Danielle Brazel, Lauren C. Pinter-Brown
Journal: Blood
Blood (2023) 142 (Supplement 1): 1749.
https://doi.org/10.1182/blood-2023-187540
Published: 2023
Journal Articles

Trial in Progress: AB-101, an Allogeneic, Non-Engineered, Cord Blood-Derived Natural Killer (NK) Cell Therapy, As Monotherapy or in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Rashmi Khanal, Jennifer N. Saultz, Umar Farooq, Sunita Nathan, Amitkumar Mehta, Ayad Hamdan, Lawrence E. Morris, Jr., Houston Holmes, Lauren C. Pinter-Brown, John K.C. Lim, Amanda Conerty, Heather Raymon, Peter Flynn, Anita G. Seto, Joseph J. Maly
Journal: Blood
Blood (2022) 140 (Supplement 1): 12742–12743.
https://doi.org/10.1182/blood-2022-159282
Published: 2022
Journal Articles

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis

Eric D Jacobsen, Pier Luigi Zinzani, Jasmine Zain, Monica Mead, Carla Casulo, Giuseppe Gritti, Lauren C. Pinter-Brown, Koji Izutsu, Marci Daugherty, Jonathan E Brammer, Neha Mehta-Shah, Barbara Pro, Steven M. Horwitz
Journal: Blood
Blood (2022) 140 (Supplement 1): 9387–9389.
https://doi.org/10.1182/blood-2022-169432
Published: 2022
Journal Articles

JAK/STAT: a pathway through the maze of PTCL?

Lauren C. Pinter-Brown
Journal: Blood
Blood (2021) 138 (26): 2747–2748.
https://doi.org/10.1182/blood.2021014238
Published: 2021
Journal Articles

First-Line Treatment with R-CHOP Vs Dose-Adjusted R-EPOCH for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis

Tamer Othman, Juan Penaloza, Elizabeth A Brem, Lauren C. Pinter-Brown, Abinav Baweja, Matthew Hyun Joon Lee, Jane Ly, Jack Reid, Haifaa Abdulhaq, Daria Gaut, Caspian Oliai, Erin G. Reid, Joseph M Tuscano
Journal: Blood
Blood (2021) 138 (Supplement 1): 2509.
https://doi.org/10.1182/blood-2021-151374
Published: 2021
Journal Articles

Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Swaminathan P. Iyer, MD, Brad M. Haverkos, MDMPH,MS, Jasmine Zain, MD, Radhakrishnan Ramchandren, MD, Mary Jo Lechowicz, MD, Sumana Devata, MD, Neil Korman, MD, Lauren C. Pinter-Brown, MD, Kasi Viswanath Routhu, PhD, Prajak Barde, MD, Ajit Mohanchandran Nair, PhD, Auris Huen, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2831.
https://doi.org/10.1182/blood-2019-123954
Published: 2019
Journal Articles

Pooled Safety Analysis and Efficacy of Tenalisib (RP6530), a PI3Kδ/γ Inhibitor, in Patients with Relapsed/Refractory Lymphoid Malignancies

Swami P. Iyer, MD, Auris Huen, MD, Andres J M Ferreri, MD, Bradley M. Haverkos, MD MPH, MS, Jasmine M. Zain, MD, Radhakrishnan Ramchandren, MD, Mary Jo Lechowicz, MD, Sumana Devata, MD, Neil Korman, MD, Lauren C. Pinter-Brown, MD, Richard Delarue, MD, Kasi V Routhu, PhD, Prajak Barde, MD, Ajit M Nair, PhD, Carmelo Carlo-Stella, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2925.
https://doi.org/10.1182/blood-2018-99-112757
Published: 2018
Journal Articles

Role of Single Agent and Combination Chemotherapy Strategies in Relapsed/Refractory Peripheral T-Cell Lymphoma: Results from the Complete Registry

Robert Stuver, MD, Niloufer Khan, MD, Marc Schwartz, Mark Acosta, Massimo Federico, MD, Christian Gisselbrecht, Frederick Lansigan, MD, Lauren C. Pinter-Brown, MD, Barbara Pro, MD, Andrei R. Shustov, MD, Steven M. Horwitz, MD, Francine M. Foss, MD, Salvia Jain, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2926.
https://doi.org/10.1182/blood-2018-99-112869
Published: 2018
Journal Articles

Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study

Youn H. Kim, MD, H. Miles Prince, MD FRACP, FRCPA, Sean Whittaker, MB, ChB, FRCP, MD, Steven M. Horwitz, MD, Madeleine Duvic, MD, Oliver Bechter, Jose A. Sanches, Rudolf Stadler, MD, Julia Scarisbrick, MD FRCP, MBBS, Pietro Quaglino, MD, Pier Luigi Zinzani, MD, Pascal Wolter, MD, Herbert Eradat, MD, Lauren C. Pinter-Brown, MD, Pablo L. Ortiz-Romero, Oleg E. Akilov, MD, Judith Trotman, FRACP, Kerry Taylor, Michael Weichenthal, MD, Jan Walewski, MD, David C. Fisher, MD PhD, Marise McNeeley, Alejandro A. Gru, MD, Yinghui Wang, MS, Maria Corinna Palanca-Wessels, MD PhD, Julie Lisano, Martha Li, Hui-Min Lin, PhD, Meredith Little, MPH, William L. Trepicchio, PhD, Reinhard Dummer, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1646.
https://doi.org/10.1182/blood-2018-99-112847
Published: 2018
Journal Articles

The Role of Upfront Hematopoietic Stem Cell Transplantation (HSCT) in Peripheral T-Cell Lymphoma (PTCL) Patients in Complete Remission (CR) with a Special Focus on Nodal PTCL: Report from the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE), a Prospective Multicenter Cohort Study

Steven I Park, MD, Steven M. Horwitz, MD, Francine M Foss, MD, Lauren C. Pinter-Brown, MD, Kenneth R. Carson, MD PhD, Steven T. Rosen, MD, Barbara Pro, MD, Eric D. Hsi, MD, Massimo Federico, Christian Gisselbrecht, MD, Marc Schwartz, Lisa A Bellm, Mark Acosta, Ranjana H. Advani, MD, Tatyana A Feldman, MD, Mary Jo Lechowicz, MD, Sonali M. Smith, MD, Frederick Lansigan, MD, Anil Tulpule, MD, Michael Craig, MD, John P. Greer, MD, Brad S Kahl, MD, Joseph W Leach, Neil Morganstein, MD, Carla Casulo, MD, Andrei R. Shustov, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 342.
https://doi.org/10.1182/blood.V130.Suppl_1.342.342
Published: 2017
Journal Articles

Phase 1 Study of the Safety and Efficacy of MRG-106, a Synthetic Inhibitor of microRNA-155, in CTCL Patients

Christiane Querfeld, MD PhD, Francine M Foss, MD, Lauren C. Pinter-Brown, MD, Pierluigi Porcu, MD, Basem M. William, MRCP,MD, Theresa Pacheco, MD, Bradley M. Haverkos, MD MPH, MS, Youn H. Kim, MD, Joan Guitart, MD, Ahmad S. Halwani, MD, Jennifer DeSimone, MD, Anita G Seto, PhD, Linda A Pestano, PhD, Aimee L Jackson, PhD, Paul J Williams, Jr., Brent A Dickinson, Judy Ruckman, PhD, Gilad Gordon, MDMBA, Paul Rubin, MD, Bill S Marshall, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 820.
https://doi.org/10.1182/blood.V130.Suppl_1.820.820
Published: 2017
Journal Articles

Differential Outcome of Patients with Primary Refractory Vs. Relapsed Peripheral T-Cell Lymphoma: Analysis from a Prospective Multicenter US Cohort Study

Frederick Lansigan, MD, Steven M Horwitz, MD, Lauren C Pinter-Brown, MD, Kenneth R Carson, MD, Andrei R Shustov, MD, Steven T. Rosen, MD, Barbara Pro, MD, Eric D. Hsi, MD, Massimo Federico, Christian Gisselbrecht, Marc Schwartz, Lisa A Bellm, MIM, Mark Acosta, PharmD, Francine M. Foss, MD
Journal: Blood
Blood (2016) 128 (22): 4150.
https://doi.org/10.1182/blood.V128.22.4150.4150
Published: 2016
Journal Articles

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma

Clinical Trials & Observations
Madeleine Duvic, Lauren C. Pinter-Brown, Francine M. Foss, Lubomir Sokol, Jeffrey L. Jorgensen, Pramoda Challagundla, Karen M. Dwyer, Xiaoping Zhang, Michael R. Kurman, Rocco Ballerini, Li Liu, Youn H. Kim
Journal: Blood
Blood (2015) 125 (12): 1883–1889.
https://doi.org/10.1182/blood-2014-09-600924
Published: 2015
Journal Articles

Phase II Preliminary Results of SGN-30 (Anti-CD30 mAb) in Patients with CD30+ Lymphoproliferative Disorders.

Madeleine Duvic, MD, Youn Kim, MD, Sunil Reddy, MD, Andres Forero-Torres, MD, Lauren C. Pinter-Brown, MD, Mark U. Rarick, MD, John Zic, MD, Sophie Worobec, MD, Neil Korman, MD, Timothy Kuzel, MD, Kimberly Bohjanen, MD, Karen Flessland, Jeremy Barton, MD, Eric Sievers, MD
Journal: Blood
Blood (2006) 108 (11): 2733.
https://doi.org/10.1182/blood.V108.11.2733.2733
Published: 2006